Ono Pharmaceutical Co. Ltd (ON4) - Total Liabilities
Based on the latest financial reports, Ono Pharmaceutical Co. Ltd (ON4) has total liabilities worth €275.84 Billion EUR as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ono Pharmaceutical Co. Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Ono Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ono Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Ono Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenergy Co Ltd
SHG:600642
|
China | CN¥63.60 Billion |
|
Terex Corporation
NYSE:TEX
|
USA | $4.04 Billion |
|
Laurus Labs Limited
NSE:LAURUSLABS
|
India | Rs44.82 Billion |
|
Shin Kong Financial Holding Co Ltd
TW:2888
|
Taiwan | NT$4.93 Trillion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
China | CN¥42.31 Billion |
|
SCREEN Holdings Co. Ltd
F:DAO
|
Germany | €237.66 Billion |
|
Informatica Inc
NYSE:INFA
|
USA | $2.85 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Ono Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ono Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ono Pharmaceutical Co. Ltd (2016–2025)
The table below shows the annual total liabilities of Ono Pharmaceutical Co. Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €275.84 Billion | +139.73% |
| 2024-03-31 | €115.06 Billion | -14.53% |
| 2023-03-31 | €134.62 Billion | +73.64% |
| 2022-03-31 | €77.53 Billion | -26.64% |
| 2021-03-31 | €105.69 Billion | +0.25% |
| 2020-03-31 | €105.42 Billion | +14.19% |
| 2019-03-31 | €92.32 Billion | +15.97% |
| 2018-03-31 | €79.61 Billion | -14.63% |
| 2017-03-31 | €93.25 Billion | +45.26% |
| 2016-03-31 | €64.19 Billion | -- |
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more